RYAH Group Inc. Partners with THC Lab to Launch Dose-Measuring Inhaler and Data Analytics Platform in Italy, Netherlands

  • Agreement between RYAH, THC Lab outlines parameters for launch of RYAH’s IoT dose-measuring Smart-Inhaler
  • Aim of agreement is to reach hundreds of pharmacies, establish RYAH as the market standard for vaporizing
  • The two companies also planning to work together on controlled research, bioavailability testing projects

RYAH Group, a leading digital health care analytics and technology company, has entered into a research-and-distribution arrangement THC Lab, which specializes in providing products and services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis (https://cnw.fm/9S8To). The agreement outlines the parameters for the launch of RYAH’s IoT dose-measuring Smart-Inhaler and data analytics platform in Italy and the Netherlands.

“We are confident that together with RYAH we will be able to increase considerably the share of inhaled medical cannabis currently estimated at only 10% in Italy and around 20% in the Netherlands,” said THC Lab sales manager Andrea Ferrari. “Our aim is to reach out to hundreds of pharmacies and establish RYAH as the market standard for vaporizing. We are extremely excited about this new partnership and see tremendous synergies with our other commercial as well as scientific activities in the medical cannabis sector.”

THC Lab appears to be an ideal partner for RYAH as the company expands globally. THC Lab has a vast network of compounding pharmacies, cannabis clinics and physicians, cannabis patient associations and pharmaceutical distributors. THC Lab will also support RYAH in further optimizing its Smart-Inhaler by providing patients the ability to provide invaluable feedback regarding the device through an integrated, in-app feedback forum.

In addition to distribution arrangements, the two companies are planning to work together in a number of controlled research and bioavailability testing projects focused on studying the effectiveness of plant-based medicines in patients with various medical conditions. “We are thrilled by this cooperation as this gives us also the opportunity to contribute to the success and development of RYAH by providing our scientific input and carrying out joint observational studies on our patients,” said THC Lab CEO and technical director Dr. Annunziata Lombardi.

A leading data and technology company, RYAH is pioneering the development of dose-measuring, plant-based delivery methods that capture vital consumption data. RYAH uses that essential data to create breakthrough discoveries aimed at advancing the validity of plant-based medicine and providing researchers with the tools needed to develop life-altering therapies.

The company is developing a suite of IoT devices, including a dry-herb inhaler device paired with the software that is capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant-dose management. Its robust AI platform is created to aggregate and correlate HIPAA-compliant medical data intended to help doctors and patients personalize plant-based treatments to predict and obtain improved treatment outcomes. The essential data collected by the company can also be used by pharmacies, clinics, growers, dispensaries and Licensed Processors (“LPs”) to monitor and manage plant strain effects on patients.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://cnw.fm/RYAH

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.


Select A Month

CBDWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 303.498.7722